Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Monday broker round-up

Mon, 11th May 2020 13:48

(Sharecast News) - Diploma: Peel Hunt downgrades to hold with a target price of 1,650p.

ITV: Berenberg reiterates hold with a target price of 88p.

Alpha Financial Markets Consulting: Berenberg reiterates buy with a target price of 190p.

Ncondezi Energy: Canaccord reiterates speculative buy with a target price of 13p.

Spire Healthcare: RBC Capital Markets downgrades to sector perform with a target price of 100p.

Superdry: RBC Capital Markets reiterates outperform with a target price of 250p.

Rolls-Royce: JP Morgan reiterates underweight with a target price of 155p.

Rio Tinto: JP Morgan reiterates neutral with a target price of 4,560p.

IMI: Deutsche Bank reiterates buy with a target price of 1,040p.

Sage Group: Deutsche Bank reiterates sell with a target price of 580p.

Rathbone Brothers: Liberum reiterates hold with a target price of 1,520p.

AstraZeneca: Liberum reiterates buy with a target price of 9,030p.

Dignity: Peel Hunt reiterates sell with a target price of 150p.

easyJet: Credit Suisse reiterates outperform with a target price of 746p.

Related Shares

More News
Today 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Today 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

Today 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.